1. Selenium supplementation for mild-to-moderate Graves ophthalmopathy (GO) was investigated in selenium-sufficient regions.
2. No significant benefit in improving quality of life or clinical outcomes was observed at 6 months. 
3. However, potential short-term improvements were noted at 3 months.
4. Selenium supplementation may have potential as an adjunct therapy for GO management.
5. The researchers suggested further investigations of selenium for GO patients are suggested because these results differ from findings in selenium-deficient populations.

Source: JAMA Ophthalmology